Can benign lymphoid tissue changes in
Antineoplastic Agents, Immunological
/ therapeutic use
Female
Fluorodeoxyglucose F18
/ pharmacokinetics
Humans
Immunotherapy
/ methods
Ipilimumab
/ therapeutic use
Lymphoid Tissue
/ diagnostic imaging
Male
Melanoma
/ immunology
Middle Aged
Neoplasm Metastasis
Positron Emission Tomography Computed Tomography
/ methods
Prognosis
Retrospective Studies
18F-FDG PET/CT
Ipilimumab
Metastatic melanoma
Spleen glucose metabolism
‘Sarcoid-like lymphadenopathy’
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
03
07
2018
accepted:
23
11
2018
pubmed:
28
11
2018
medline:
26
2
2019
entrez:
28
11
2018
Statut:
ppublish
Résumé
An association between immune-related adverse events (irAEs) caused by immunotherapeutic agents and the clinical benefit of immunotherapy has been suggested. We retrospectively evaluated by means of A total of 41 patients with unresectable metastatic melanoma underwent According to the BCR reference, 31 patients showed disease control (DC) and 10 patients showed progressive disease (PD). Mediastinal/hilar lymph node evaluation revealed that in total 4 patients in the interim or late PET/CT (10%) demonstrated a 'sarcoid-like lymphadenopathy' as response to treatment (LN-positive). All LN-positive patients responded to ipilimumab with DC. On the other hand, no significant differences between the DC and PD groups regarding both semi-quantitative and quantitative Based on our findings, 10% patients in the interim or late PET/CT showed 'sarcoid-like lymphadenopathy' as response to treatment. All these patients showed disease control, implying a relation between the appearance of sarcoid-like lymphadenopathy and the clinical benefit of anti-CTLA-4 therapy. On the other hand, quantitative
Sections du résumé
BACKGROUND
BACKGROUND
An association between immune-related adverse events (irAEs) caused by immunotherapeutic agents and the clinical benefit of immunotherapy has been suggested. We retrospectively evaluated by means of
METHODS
METHODS
A total of 41 patients with unresectable metastatic melanoma underwent
RESULTS
RESULTS
According to the BCR reference, 31 patients showed disease control (DC) and 10 patients showed progressive disease (PD). Mediastinal/hilar lymph node evaluation revealed that in total 4 patients in the interim or late PET/CT (10%) demonstrated a 'sarcoid-like lymphadenopathy' as response to treatment (LN-positive). All LN-positive patients responded to ipilimumab with DC. On the other hand, no significant differences between the DC and PD groups regarding both semi-quantitative and quantitative
CONCLUSION
CONCLUSIONS
Based on our findings, 10% patients in the interim or late PET/CT showed 'sarcoid-like lymphadenopathy' as response to treatment. All these patients showed disease control, implying a relation between the appearance of sarcoid-like lymphadenopathy and the clinical benefit of anti-CTLA-4 therapy. On the other hand, quantitative
Identifiants
pubmed: 30478475
doi: 10.1007/s00262-018-2279-9
pii: 10.1007/s00262-018-2279-9
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Ipilimumab
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM